Literature DB >> 8431927

Strategies for prevention of anthracycline cardiotoxicity.

R L Basser1, M D Green.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8431927     DOI： 10.1016/0305-7372(93)90027-o

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  12 in total

Review 1.  A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy.

Authors:  R Abraham; R L Basser; M D Green
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

2.  Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.

Authors:  Lubomir Elbl; Hana Hrstkova; Iva Tomaskova; Bohumir Blazek; Jaroslav Michalek
Journal:  Eur J Pediatr       Date:  2005-07-26       Impact factor: 3.183

3.  Differences in accumulation of anthracyclines daunorubicin, doxorubicin and epirubicin in rat tissues revealed by immunocytochemistry.

Authors:  Masashi Shin; Hayato Matsunaga; Kunio Fujiwara
Journal:  Histochem Cell Biol       Date:  2010-04-28       Impact factor: 4.304

4.  Phase II trial of pre-irradiation KRN8602 (MX2) in malignant glioma patients.

Authors:  J I Kuratsu; N Arita; T Kayama; N Kubo; T Mori; Y Sawamura; Y Ushio
Journal:  J Neurooncol       Date:  2000-06       Impact factor: 4.130

5.  Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.

Authors:  Lubomir Elbl; Hana Hrstkova; Iva Tomaskova; Jaroslav Michalek
Journal:  Support Care Cancer       Date:  2005-07-21       Impact factor: 3.603

6.  Doxorubicin-heparin complex: reduction of cardiotoxicity of doxorubicin.

Authors:  Y Mizuno; T Hara; S Tachibana; K Uragoh; K Akazawa; K Ueda
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

Review 7.  Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): progress in supportive care.

Authors:  K Hellmann
Journal:  Support Care Cancer       Date:  1996-07       Impact factor: 3.603

8.  Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen.

Authors:  S Jelić; S Radulović; Z Nesković-Konstantinović; M Kreacić; Z Ristović; S Bosnjak; N Milanović; L Vuletić
Journal:  Support Care Cancer       Date:  1995-05       Impact factor: 3.603

9.  The Current and Future Therapies for Human Osteosarcoma.

Authors:  Joseph D Lamplot; Sahitya Denduluri; Jiaqiang Qin; Ruidong Li; Xing Liu; Hongyu Zhang; Xiang Chen; Ning Wang; Abdullah Pratt; Wei Shui; Xiaoji Luo; Guoxin Nan; Zhong-Liang Deng; Jinyong Luo; Rex C Haydon; Tong-Chuan He; Hue H Luu
Journal:  Curr Cancer Ther Rev       Date:  2013-02

10.  Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.

Authors:  P Pouna; S Bonoron-Adèle; G Gouverneur; L Tariosse; P Besse; J Robert
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.